0.2800 -0.00 (-0.53%)
After hours: 4:00PM EST
| Previous Close | 0.3012 |
| Open | 0.3000 |
| Bid | 0.2800 x 3100 |
| Ask | 0.3025 x 1000 |
| Day's Range | 0.2730 - 0.3100 |
| 52 Week Range | 0.2500 - 1.7500 |
| Volume | 975,012 |
| Avg. Volume | 666,850 |
| Market Cap | 6.518M |
| Beta (3Y Monthly) | 2.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5660 |
| Earnings Date | Nov 19, 2018 - Nov 20, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), yesterday filed a proxy statement in advance of a special shareholder meeting scheduled for December 20th, 2018. Please see below a brief statement from Ilan Danieli, Precipio’s CEO. The purpose of the proposals in the proxy is to create options for the company, to ensure that management has the ability to act quickly in the best interest of the company to protect value to its shareholders.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be hosting its third quarter 2018 corporate update call on Monday, November 19 at 5:00 PM ET, following the expected filing on or before November 19 of its form 10-Q and release of its financial results for the quarter ended September 30, 2018. The conference call may be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). All callers should ask for the Precipio Inc. conference call.
CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / Healthcare demand is increasing as an aging population continues to drive new healthcare market growth. The connection between healthcare goods and services is less tied to the economy compared to other sectors, and that could make healthcare stocks the place where investors will look for a hedge as the broader markets see increasing volatility. According to Bureau of Labor Statistics data*, the fastest-growing sectors include healthcare support occupations (23.2% increase from 2016-2026) and healthcare practitioners and technical occupations (15.2%), which entail home health aides, physician assistants and nurse practitioners, among other positions.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces an upcoming Labroots webinar titled “COLD-PCR technology: current status and application in liquid biopsies for cancer and prenatal diagnosis” on Tuesday, November 20th at 10:00 AM EST (7:00AM PST). The webinar is sponsored by Perkin Elmer and attendees will receive either Professional Acknowledgment for Continuing Education (P.A.C.E.®) or Florida C.E. credit.
Precipio ICE COLD-PCR™ reagents will be sold with PerkinElmer DNA/RNA extraction and isolation products NEW HAVEN, Conn., Nov. 01, 2018 -- Specialty cancer diagnostics company.
NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched two new ICEme™ assays using its proprietary ICE-COLD PCR technology. The new ICEme assays cover PIK3CA exons 9 & 20, and achieve a level of sensitivity of 0.1%, enabling their use with liquid biopsies. PIK3CA mutations occur in about 25% to 40% of breast cancer, 36% of endometrial cancer, and 32% of colon cancers.1 Presence of PIK3CA mutations is associated with resistance to various therapies for breast cancer patients, and in fact have indicated resistance to therapies, thus requiring different or more aggressive treatment.
The scientific and economic advantages of the proprietary, ultra-sensitive ICE-COLD PCR (ICP) technology developed by specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) were recently spotlighted in several industry media outlets. A Drug Delivery Business News article titled “Tracking tumors with Precipio’s liquid biopsy tech” discusses the role liquid biopsies can play in cancer treatment and why the economics of monitoring is important. A Clinical Lab Products article titled “Inside Track: In the Trenches” provides a Q&A with Precipio CEO Ilan Danieli.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced preliminary third quarter results representing continued triple digit percentage year-over-year quarterly revenue growth. Pathology services, Precipio’s core business, showed quarter over quarter sequential growth of approximately 20%. Management will review the drivers of pathology services in its upcoming shareholder conference call following the SEC filing of Precipio’s third quarter 2018 results.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the commercial launch of HemeScreen, a novel proprietary test for mutations in hematologic cancers. Precipio is the first to offer a low cost, rapid molecular screening panel for hematologic mutations. Reagents: A set of RUO reagents sold to other reference labs to perform the test in their CLIA laboratories.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum $1.00 per share closing bid price of its common stock for 10 consecutive business days for continued inclusion on the Nasdaq Capital Market Exchange. “These additional six months provide more time for our operational, commercial and strategic initiatives to materialize, and for management to build the value of the company,” commented Ilan Danieli, Precipio’s CEO.
Specialty cancer diagnostics Company Precipio, Inc. (NASDAQ: PRPO), announces the restructuring of its remaining legacy, pre-merger accounts payable liabilities, pursuant to an exchange which is made in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933. The payments made to note holders are equal to approximately 20% of the original $5.3 million, and are funded through a convertible note with existing investors. Important benefits of this transaction include the postponement of $82,000 in monthly debt service for a period of 12 months, and the ability during that time to convert the notes at a 65% premium to market, effectively reducing by almost half the dilution that would have otherwise resulted from raising capital necessary to satisfy these obligations.
The kit provides physicians the ability to use a liquid biopsy to identify patients eligible for Tyrosine Kinase Inhibitor (TKI) therapies through analysis of tumor DNA for these critical EGFR mutations. The presence of such mutations indicates the patient’s eligibility for various targeted therapies including TKI. This kit complements Precipio’s previously-launched TKI-resistance detection kit, providing the clinician with a full suite of sequential lung-cancer diagnostic tools critical to determining patient treatment.
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Precipio, Inc. (NASDAQ: PRPO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 23, 2018 at 9:00 AM Eastern Time. To ...
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), wishes to remind investors and shareholders of its previously announced shareholder conference call scheduled for tomorrow, Thursday August 23, 2018 at 9:00 am EDT, where management will provide a strategic business update and address questions submitted in advance via email. All callers should ask for the Precipio Inc., conference call. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Texas Instruments Incorporated closed down modestly on Wednesday. The company's CEO Brian Crutcher recently resigned for violating conduct and in his place, former CEO Rich Templeton has taken his position. Shares of Precipio saw big gains after announcing preliminary second quarter results.
Stock Research Monitor: PKI, PRAH, and PRPO LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on DGX sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...